Retatrutide vs Tirzepatide vs Semaglutide: Comparing GLP-1 Research Compounds 2026 | Daxer Labs

Q: What's the main structural difference between these three compounds?

Semaglutide is a single-receptor GLP-1 agonist, Tirzepatide is a dual GLP-1/GIP agonist, and Retatrutide is a triple agonist acting on GLP-1, GIP, and glucagon receptors — each representing a successive generation of receptor targeting in metabolic research.

Q: Which compound has the longest research history?

Semaglutide has the longest established research and clinical literature, followed by Tirzepatide; Retatrutide is the newest of the three and has a comparatively smaller but rapidly growing body of published research.

Q: Are these compounds interchangeable in a research protocol?

No — each has a distinct receptor-binding profile, so substituting one for another in a research protocol changes exactly what's being studied and should only be done with a clear rationale for the compound switch.

Daxer Labs

Jul 31

2 min read

Three Generations of GLP-1 Research Compounds

Semaglutide, Tirzepatide, and Retatrutide represent three successive generations of receptor targeting in GLP-1 metabolic research, each broadening the receptor profile of the one before it. Understanding what separates them matters for researchers deciding which compound fits a given study design.

Semaglutide: Single-Receptor GLP-1 Agonist

Semaglutide acts on the GLP-1 receptor alone and has by far the longest and deepest body of published research behind it, making it a well-characterised reference compound for metabolic and appetite-regulation studies.

Tirzepatide: Dual GLP-1/GIP Agonist

Tirzepatide extends the receptor profile to include GIP alongside GLP-1, reflecting research interest in whether dual-incretin activity produces different metabolic effects than GLP-1 activity alone. Its research literature is smaller than Semaglutide's but has grown quickly.

Retatrutide: Triple Agonist

Retatrutide goes a step further, targeting GLP-1, GIP, and glucagon receptors simultaneously. As the newest of the three, it has the smallest published research base, but early findings have made it one of the most closely watched compounds in this research area.

Choosing a Compound for a Research Protocol

The right compound depends on the specific receptor pathway a study is designed around — a single-receptor reference compound like Semaglutide serves a different purpose than a multi-receptor compound like Tirzepatide or Retatrutide. These are not interchangeable substitutes for one another.

Sourcing All Three from Daxer Labs

Daxer Labs supplies Retatrutide, Tirzepatide, and Semaglutide as Swiss-manufactured research compounds, each with full HPLC-verified Certificates of Analysis, so researchers can compare purity and documentation standards across all three in one place.

Frequently Asked Questions

What's the main structural difference between these three compounds? Semaglutide targets GLP-1 alone, Tirzepatide targets GLP-1 and GIP, and Retatrutide targets GLP-1, GIP, and glucagon receptors.

Which compound has the longest research history? Semaglutide, followed by Tirzepatide, with Retatrutide being the newest and least studied of the three.

Are these compounds interchangeable in a research protocol? No — each has a distinct receptor profile, so the choice should be based on the specific pathway a study is examining.